Douglas, IsleMan, Isle of Man
Declan Doogan, Greg Bailey, Jim Mellon
2016
Juvenescence is a biopharmaceutical company that has raised USD $168 million since 2017 to build a pipeline of therapeutic assets to target aging, regeneration and the diseases of aging.
The problem
As people age, complex changes occur at the genomic, cellular and tissue level, from the accumulation of DNA damage to mitochondrial dysfunction and altered intercellular communication.
These changes, among others, cause the diseases of aging that affect the elderly, and the chronic illnesses that are the biggest burden on the healthcare system.
Aging is the largest health problem facing the world today; two-thirds of all deaths worldwide are as a result of the aging process, with many years of degeneration reducing quality of life before death.
The Problems with aging
Our work is based on novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging.
Juvenescence creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions.
The goal
Juvenescence aims to create a paradigm shift in addressing and treating disease.
Our goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence (”the state or period of being young”).
Ultimately, Juvenescence aims to get therapeutics to patients, and eradicate life-shattering diseases that cause people to suffer until death.
Our Goals
Collaboration
At Juvenescence, we work with leading research institutions and the world’s foremost longevity scientists to create joint ventures developing evidence-based therapeutics.